Northern Trust Corp Has $10.67 Million Holdings in BioLife Solutions, Inc. (NASDAQ:BLFS)

Northern Trust Corp grew its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 7.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 411,033 shares of the medical equipment provider’s stock after purchasing an additional 30,217 shares during the period. Northern Trust Corp owned about 0.89% of BioLife Solutions worth $10,670,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of BLFS. Steward Partners Investment Advisory LLC bought a new stake in shares of BioLife Solutions in the fourth quarter valued at about $26,000. 1620 Investment Advisors Inc. boosted its stake in BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after buying an additional 675 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in BioLife Solutions by 27.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock worth $117,000 after acquiring an additional 950 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of BioLife Solutions in the 4th quarter worth about $171,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in BioLife Solutions during the 4th quarter worth approximately $201,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BLFS. StockNews.com raised shares of BioLife Solutions from a “sell” rating to a “hold” rating in a report on Tuesday, May 13th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Tuesday, May 13th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, BioLife Solutions has an average rating of “Moderate Buy” and a consensus target price of $31.17.

BioLife Solutions Price Performance

NASDAQ BLFS opened at $23.59 on Friday. The company has a market capitalization of $1.12 billion, a PE ratio of -22.25 and a beta of 2.01. The firm’s 50 day moving average is $23.52 and its 200-day moving average is $25.29. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12-month low of $18.70 and a 12-month high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last released its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.07. The business had revenue of $23.94 million during the quarter, compared to analysts’ expectations of $22.22 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. Equities research analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, CMO Todd Berard sold 1,577 shares of BioLife Solutions stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $39,425.00. Following the completion of the sale, the chief marketing officer now owns 104,961 shares in the company, valued at $2,624,025. The trade was a 1.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sarah Aebersold sold 5,771 shares of the business’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total transaction of $130,770.86. Following the transaction, the insider now owns 80,094 shares of the company’s stock, valued at approximately $1,814,930.04. This represents a 6.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 71,696 shares of company stock worth $1,665,094. 2.20% of the stock is owned by company insiders.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.